is busy trading, always.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MCP blocks
Bot more
He most likely took the screen shot around 8AM
SPY not once over yesterday's HOD in pre-M
Boone on CNBC any minute now.
MAKO not on that list? GM Zo
MAKO > $41.50 weeeeeeeeeeeeeeeeeeeeee
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=71328034
FUTURES: DOW +61.00 / NASDAQ +14.00 / S&P +7.00
MAKO pushing $40.50 LOVELY
Ford Awards Mulally $58.3 Million
http://tinyurl.com/7yub9zm
Ford has awarded him stock worth more than $100 million the past two years
CF weakness a buying opportunity, says Morgan Stanley
Morgan Stanley recommends buying CF Industries on recent market related weakness following two days of investor meetings. The firm said views valuation as compelling and expects the company to use cash for large share repurchases. The firm rates CF Industries an Overweight with a $125 price target
GM Zed. Futures up but took 18 hours for the S&P to move 10 points. Hmmm
$10.00 - $9.50
SPY @ yesterday's opening pps
FUTURES: DOW +51.00 / NASDAQ +12.50 / S&P +5.50
GM Fed, sure. All you have to do is kill the Batman.
Unit labor costs +2.8% exp +1.2%
Nonfarm productivity +0.9% exp +0.8%
DSCO could be acquired, says Roth Capital
After Discovery Labs' synthetic surfactant, Surfaxin, was approved by the FDA, Roth Capital thinks the company could sell itself, or obtain a partner. The firm believes that the FDA's approval significantly increases the value of the company's stock, and it raised its target on the shares to $10 from $6 while maintaining a Buy rating
AAPL up $20.00 from yesterday's LOD
Orchid Fund reports 5.1% passive stake in IOC (2 days old)
GOOG cuts price of cloud storage by 15%
The 20 richest people on Earth lost a combined $11.3 billion yesterday
P < $11.00
+216,000 in line ADP
AAPL pushing $535
MAKO should be bought at current levels, says Piper Jaffray
Piper Jaffray believes Mako Surgical remains on track after posting in-line Q4 results and reiterating 2012 guidance for robot placements and implants of 56-62 and 11,000-13,000, respectively. The firm said it would be an aggressive buyer of the stock at current levels and reiterates an Overweight rating on the name with a $50 price target.
MAKO pushing $39.00, goes higher
FUTURES: DOW +51.00 / NASDAQ +12.50 / S&P +5.75
GOOD MORNING.
Energizing, bbl SSS
MAKO...really ? Holding.
SURFAXIN will be commercially available in the United States in late 2012
2,258 MAKOplasty procedures performed in Q4, a 97% increase over the same period in 2010.
MAKO Reports Q4 revenue $32.9M, consensus $30.72M. Eighteen RIO systems sold in Q4, increasing worldwide commercial installed base to 113 RIO systems and domestic commercial installed base to 111 RIO systems. 2,258 MAKOplasty procedures performed in Q4, a 97% increase over the same period in 2010. 37 MAKOplasty Total Hip Arthroplasty applications sold in Q4.
AVAV halted, news pending
The bid just went up $0.20 lol